Boston Scientific Corp (BSX)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $64.27B
Last updated: Nov 17, 2026 at 11:05 AM ET
Boston Scientific Corp (BSX) Financials: Revenue, Profit and Cash Flow
Boston Scientific reported revenue of $20.07B for the fiscal year ended Dec 31, 2025, up 19.9% from the year before. That year, net income was $2.89B with a net margin of 14.4%, operating cash flow was $4.53B and free cash flow was $3.66B. The quarter ended Sep 30, 2026 had revenue of $5.14B and net income of $580.00M.
Revenue and Margins
The operating margin was 18.0% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $8.39B, a compound annual rate of 10.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $20.07B | +19.9% | 69.0% | 18.0% | 14.4% |
| Dec 2024 | $16.75B | +17.6% | 68.6% | 15.5% | 11.0% |
| Dec 2023 | $14.24B | +12.3% | 69.5% | 16.5% | 11.2% |
| Dec 2022 | $12.68B | +6.7% | 68.8% | 13.0% | 5.5% |
| Dec 2021 | $11.89B | +19.9% | 68.8% | 10.1% | 8.8% |
| Dec 2020 | $9.91B | -7.7% | 65.0% | -0.8% | -0.8% |
| Dec 2019 | $10.73B | +9.3% | 71.0% | 14.1% | 43.8% |
| Dec 2018 | $9.82B | +8.6% | 71.4% | 15.3% | 17.0% |
| Dec 2017 | $9.05B | +7.9% | 71.3% | 14.2% | 1.1% |
| Dec 2016 | $8.39B | N/A | 71.1% | 5.3% | 4.1% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 56.2% from the year before. In the quarter ended Sep 2026, net income fell 23.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B | $9.82B | $9.05B | $8.39B |
| Cost of revenue | $6.22B | $5.26B | $4.34B | $3.96B | $3.71B | $3.46B | $3.12B | $2.81B | $2.59B | $2.42B |
| Gross profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B | $6.45B | $7.62B | $7.01B | $6.46B | $5.96B |
| Research and development | $2.05B | $1.61B | $1.41B | $1.32B | $1.20B | $1.14B | $1.17B | $1.11B | $997.00M | $920.00M |
| Operating income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B | -$80.00M | $1.52B | $1.51B | $1.28B | $447.00M |
| Net income | $2.89B | $1.85B | $1.59B | $698.00M | $1.04B | -$82.00M | $4.70B | $1.67B | $104.00M | $347.00M |
| EBITDA | $5.23B | $3.91B | $3.45B | $2.78B | $2.54B | $1.46B | $2.22B | $2.56B | $2.02B | $1.25B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | $4.66B | $4.56B | $4.21B | $4.12B | $3.86B | $3.73B |
| Gross profit | $3.43B | $3.85B | $3.61B | $3.68B | $3.54B | $3.42B | $3.21B | $3.10B | $2.90B | $2.85B | $2.65B | $2.58B |
| Operating income | $828.00M | $1.18B | $1.10B | $825.00M | $1.05B | $819.00M | $921.00M | $675.00M | $733.00M | $520.00M | $675.00M | $584.00M |
| Net income | $580.00M | $905.00M | $1.34B | $670.00M | $755.00M | $795.00M | $672.00M | $563.00M | $468.00M | $322.00M | $493.00M | $504.00M |
Balance Sheet
As of Dec 2025, total debt of $11.44B exceeded cash and equivalents by $9.47B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B | $30.78B | $30.57B | $21.00B | $19.04B | $18.10B |
| Current assets | $8.79B | $6.92B | $6.51B | $5.76B | $6.32B | $6.69B | $4.70B | $4.00B | $3.82B | $3.24B |
| Cash and equivalents | $1.97B | $414.00M | $865.00M | $928.00M | $1.93B | $1.73B | $217.00M | $146.00M | $188.00M | $196.00M |
| Total liabilities | $19.20B | $17.39B | $15.61B | $14.90B | $15.61B | $15.45B | $16.69B | $12.27B | $12.03B | $11.36B |
| Short-term debt | $299.00M | $1.78B | $531.00M | $20.00M | $261.00M | $13.00M | $1.42B | $2.25B | $1.80B | $64.00M |
| Long-term debt | $11.14B | $8.97B | $8.57B | $8.91B | $8.80B | $9.13B | $8.59B | $4.80B | $3.81B | $5.42B |
| Shareholder equity | $24.23B | $21.77B | $19.28B | $17.57B | $16.62B | $15.34B | $13.88B | $8.73B | $7.01B | $6.73B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $45.46B | $45.22B | $44.35B | $43.67B | $42.71B | $41.56B | $40.14B | $39.40B | $38.08B | $37.11B | $36.67B | $35.14B |
| Total liabilities | $19.59B | $20.04B | $18.25B | $19.20B | $19.08B | $18.91B | $17.69B | $17.39B | $17.12B | $16.50B | $16.50B | $15.61B |
| Cash and equivalents | $609.00M | $539.00M | $1.45B | $2.04B | $1.27B | $534.00M | $725.00M | $414.00M | $2.50B | $2.91B | $2.33B | $865.00M |
| Shareholder equity | $25.63B | $24.93B | $25.86B | $24.23B | $23.39B | $22.42B | $22.21B | $21.77B | $20.71B | $20.37B | $19.93B | $19.28B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 80.8% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.53B | $3.44B | $2.50B | $1.53B | $1.87B | $1.51B | $1.84B | $310.00M | $1.43B | $1.18B |
| Capital expenditures | $876.00M | $790.00M | $711.00M | $588.00M | $554.00M | $376.00M | $461.00M | $316.00M | $319.00M | $376.00M |
| Free cash flow | $3.66B | $2.65B | $1.79B | $938.00M | $1.32B | $1.13B | $1.38B | -$6.00M | $1.11B | $806.00M |
| Dividends paid | N/A | $0 | $28.00M | $55.00M | $55.00M | $28.00M | $0 | $0 | $28.00M | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $535.00M | $0 | $0 | N/A | N/A |
| Investing cash flow | -$2.64B | -$5.69B | -$2.57B | -$2.01B | -$1.60B | -$411.00M | -$5.04B | -$1.92B | -$1.01B | -$887.00M |
| Financing cash flow | -$395.00M | $1.81B | $5.00M | -$548.00M | -$95.00M | $293.00M | $2.97B | $1.43B | $110.00M | -$206.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.05B | $1.47B | $348.00M | $1.36B | $1.34B | $1.29B | $541.00M | $1.46B | $1.00B | $813.00M | $164.00M | $957.00M |
| Capital expenditures | $180.00M | $195.00M | $177.00M | $351.00M | $181.00M | $157.00M | $187.00M | $277.00M | $179.00M | $155.00M | $179.00M | $267.00M |
| Free cash flow | $868.00M | $1.28B | $171.00M | $1.01B | $1.16B | $1.13B | $354.00M | $1.18B | $823.00M | $658.00M | -$15.00M | $690.00M |
Frequently Asked Questions About BSX
What is Boston Scientific's annual revenue?
Boston Scientific reported revenue of $20.07B for the fiscal year ended Dec 31, 2025.
How fast is Boston Scientific's revenue growing?
Revenue was up 19.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.5%.
Is Boston Scientific profitable?
Yes. Boston Scientific reported net income of $2.89B for the fiscal year ended Dec 31, 2025, with a net margin of 14.4%.
How much free cash flow does BSX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $4.53B minus capital expenditures of $876.00M produced free cash flow of $3.66B.
How much debt does Boston Scientific have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $11.14B, short-term debt of $299.00M and cash and equivalents of $1.97B.
BSX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts